Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.

[1]  W. Delaney.  Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. , 2007, The Journal of antimicrobial chemotherapy.

[2]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[3]  F. Zoulim,et al.  A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV–hepatitis B virus-co-infected patient , 2006, AIDS.

[4]  M. Helm,et al.  Variant of hepatitis B virus with primary resistance to adefovir. , 2006, The New England journal of medicine.

[5]  J. Pawlotsky,et al.  483 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients , 2006 .

[6]  Angeline Bartholomeusz,et al.  HBV drug resistance: mechanisms, detection and interpretation. , 2006, Journal of hepatology.

[7]  T. Asselah,et al.  Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. , 2005, Journal of hepatology.

[8]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[9]  P. Marcellin,et al.  A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B , 2004, Hepatology.

[10]  B. Tehan,et al.  Comparisons of the Hbv and HIV Polymerase, and Antiviral Resistance Mutations , 2003, Antiviral therapy.

[11]  M. Wulfsohn,et al.  Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients , 2003, Hepatology.

[12]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[13]  M. Wulfsohn,et al.  Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B , 2003, Hepatology.

[14]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[16]  C. Chu,et al.  Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy , 2000, Hepatology.

[17]  M. Manns,et al.  Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation , 1999, Hepatology.

[18]  D. Richman.  The implications of drug resistance for strategies of combination antiviral chemotherapy. , 1996, Antiviral research.

[19]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[20]  I Sauvaget,et al.  Identification of four conserved motifs among the RNA‐dependent polymerase encoding elements. , 1989, The EMBO journal.